China antibody-B (03681.HK) released its interim performance with a research and development cost of 32.74 million yuan. Both core drug pipelines have made significant breakthroughs.

WisePay Finance APP News, China Antibody-B (03681.HK) released its mid-year performance for 2025, with other income and revenue of 9.802 million yuan (RMB, the same below), an increase of 126.95% year-on-year; research and development costs were 32.74 million yuan.